Outcomes with durvalumab and savolitinib in metastatic papillary renal cancer (mPRC) according to international metastatic renal cell carcinoma database consortium (IMDC) risk groups

Simple item page
dc.conference.dateDEC 09-12, 2020
dc.conference.titleESMO Immuno-Oncology Virtual Congress
dc.contributor.authorChoy, J.
dc.contributor.authorSuarez Rodriguez, C.
dc.contributor.authorLarkin, J.
dc.contributor.authorPatel, P.
dc.contributor.authorPerez Valderrama, B.
dc.contributor.authorRodriguez-Vida, A.
dc.contributor.authorGlen, H.
dc.contributor.authorThistlethwaite, F.
dc.contributor.authorRalph, C.
dc.contributor.authorSrinivasan, G.
dc.contributor.authorMendez Vidal, M. J.
dc.contributor.authorCarter, A.
dc.contributor.authorTyson, C.
dc.contributor.authorPrendergast, A.
dc.contributor.authorMousa, K.
dc.contributor.authorPowles, T. B.
dc.contributor.authorSzabados, B. E.
dc.contributor.authoraffiliation[Choy, J.] Barts Canc Inst, Dept Oncol, London, England
dc.contributor.authoraffiliation[Carter, A.] Barts Canc Inst, Dept Oncol, London, England
dc.contributor.authoraffiliation[Tyson, C.] Barts Canc Inst, Dept Oncol, London, England
dc.contributor.authoraffiliation[Prendergast, A.] Barts Canc Inst, Dept Oncol, London, England
dc.contributor.authoraffiliation[Mousa, K.] Barts Canc Inst, Dept Oncol, London, England
dc.contributor.authoraffiliation[Suarez Rodriguez, C.] Vall Hebron Univ Hosp, Inst Oncol, Oncol Dept, Barcelona, Spain
dc.contributor.authoraffiliation[Larkin, J.] Royal Marsden Hosp NHS Fdn Trust, Med Dept, London, England
dc.contributor.authoraffiliation[Patel, P.] Nottingham Univ NHS Trust, Med Oncol, Nottingham, England
dc.contributor.authoraffiliation[Perez Valderrama, B.] Hosp Univ Virgen del Rocio, Med Oncol, Seville, Spain
dc.contributor.authoraffiliation[Rodriguez-Vida, A.] Hosp del Mar, Med Oncol, Barcelona, Spain
dc.contributor.authoraffiliation[Glen, H.] NHS Greater Glasgow & Clyde, BWSCC Beatson West Scotland Canc Ctr, Med Oncol, Glasgow, Lanark, Scotland
dc.contributor.authoraffiliation[Thistlethwaite, F.] Christie NHS Fdn Trust, Med Oncol, Manchester, Lancs, England
dc.contributor.authoraffiliation[Ralph, C.] St Jamess Univ Hosp Leeds, Med Oncol, Leeds, W Yorkshire, England
dc.contributor.authoraffiliation[Srinivasan, G.] Broomfield Hosp, Med Oncol, Broomfield, Essex, England
dc.contributor.authoraffiliation[Mendez Vidal, M. J.] Hosp Univ Reina Sofia, Med Oncol, Cordoba, Spain
dc.contributor.authoraffiliation[Powles, T. B.] Barts Hlth NHS Trust, St Bartholomews Hosp, Oncol Dept, London, England
dc.contributor.authoraffiliation[Szabados, B. E.] Barts Canc Inst, Dept Med Oncol, London, England
dc.contributor.funderAstraZeneca
dc.date.accessioned2025-01-07T15:48:53Z
dc.date.available2025-01-07T15:48:53Z
dc.date.issued2020-12-01
dc.identifier.doi10.1016/j.annonc.2020.10.557
dc.identifier.essn1569-8041
dc.identifier.issn0923-7534
dc.identifier.unpaywallURLhttp://www.annalsofoncology.org/article/S0923753420430704/pdf
dc.identifier.urihttps://hdl.handle.net/10668/27421
dc.identifier.wosID600992500070
dc.issue.number7
dc.journal.titleAnnals of oncology
dc.journal.titleabbreviationAnn. oncol.
dc.language.isoen
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.organizationSAS - Hospital Universitario Virgen del Rocío
dc.page.numberS1446-S1446
dc.publisherElsevier
dc.rights.accessRightsopen access
dc.titleOutcomes with durvalumab and savolitinib in metastatic papillary renal cancer (mPRC) according to international metastatic renal cell carcinoma database consortium (IMDC) risk groups
dc.typeconference output
dc.type.hasVersionVoR
dc.volume.number31
dc.wostypeMeeting Abstract

Files

Collections

Instituto de Investigación Biomédica de Sevilla (IBIS)
SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía